drugset / Trial / NCT01352234

Comparison of Doses of Acetylsalicylic Acid in Women With Previous History of Preeclampsia

NCT01352234 ↗

Phase 4 Completed 104 enrolled CHU de Quebec-Universite Laval
RandomizedParallel-groupQuadruple-blindPrevention

Summary

Placental insufficiency is the source of preeclampsia (PE) and intrauterine growth retardation (IUGR). Current data demonstrate a significant beneficial effect of prophylactic use of aspirin on the recurrence of placental insufficiency and its complications, mainly preeclampsia, when started early in pregnancy. However, there is a significant heterogeneity in medical practice in Canada and around the world in terms of the dose of aspirin used. The objectives of this study are: 1) Evaluate whether a dose of 160 mg of aspirin is associated with greater improvement in placental function assessed by biochemistry (sFlt-1 and endoglin) and ultrasound (uterine artery Doppler) than a dose of 80 mg in women with a history of PE, 2) Assess whether the change is dependent on platelet aggregation measured by a test used in several Canadian centers (PFA-100).

Timeline

Start
2011-09
Primary completion
2014-12
Completion
2015-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Aspirin Small molecule 80 mg —
Subject Aspirin Small molecule 160 mg —